[Business Wire] – Pfizer Inc. announced today top-line results from a Phase 3B/4 study of RAPAMUNE® evaluating kidney transplant patients who transitioned from tacrolimus-based therapy to RAPAMUNE® 3 to 5 months after transplant.
Read more on this.
Pfizer Inc. (PFE), with a current value of … [visit site to read more]
Similar posts: